Literature DB >> 16237717

Recurrence of hepatitis C infection: Where are we now?

Michael Charlton1.   

Abstract

1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving. (

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237717     DOI: 10.1002/lt.20597

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  3 in total

Review 1.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

2.  Antiviral therapy for hepatitis C in the setting of liver transplantation.

Authors:  Gregory T Everson; Clark C Kulig
Journal:  Curr Treat Options Gastroenterol       Date:  2006

3.  Oxidative stress response in patients infected by diverse hepatitis C virus genotypes.

Authors:  Mohammad Hassan Khadem Ansari; Mir-Davood Omrani; Fatemeh Kheradmand
Journal:  Hepat Mon       Date:  2015-02-21       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.